Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus

KNOXVILLE, Tenn., March 6, 2017 /PRNewswire/ — Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has extended the expiration date of its rights offe

To Top